Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Final completion of the ECLIPSE trial is anticipated for February 2029.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.

In total, the study plans to enroll 84 adult patients across clinical trial sites in the United States and Australia.